Comparative vasoconstrictor effects of angiotensin II, III, and IV in human isolated saphenous vein

Elevated levels of angiotensin (Ang II) and its degradation products angiotensin III (Ang III) and angiotensin IV (Ang (IV) may contribute to the regulation of vascular tone under various clinical circumstances. We investigated the contractile effects of Ang III and Ang IV in endothelium-denuded human saphenous vein (SV) preparations and compared them with those of Ang II. The veins were suspended in organ chambers, and changes in isometric force were recorded. Ang II (0.1-100 nM), Ang III (1 nM-3 mu M), and Ang IV (0.3 mu M-0.1 mM) caused concentration-dependent contractions with comparable maximal responses (E-max). Ang III was 16 times less active than Ang II, whereas Ang IV was similar to 2,700-fold less potent than Ang II. In the presence of the aminopeptidase-A and -M inhibitor amastatin (10 mu M), the potencies of Ang III and Ang IV were increased by similar to 16 and 12 times, respectively, although no changes of Ang II potency were observed. The AT(1)-selective Ang II receptor antagonist losartan (10 and 100 nM) but not the AT(2)-selective antagonist PD123177 (1 mu M), shifted the concentration-response curves (CRC) for the angiotensin peptides to the right in a parallel manner. Preincubation with indomethacin (10 mu M), a cyclooxygenase inhibitor, did not influence the CRCs for any of the angiotensin peptides studied. Tachyphylaxis was investigated by constructing a second series of CRCs for the angiotensin peptides after an interval of 60 min. Ang II showed strong tachyphylaxis (the E-max value of the second Ang II CRC was similar to 50% of the first), whereas Ang III and Ang IV did not. Our results indicate that in endothelium-denuded human SV, both Ang III and Ang IV are less potent but similarly efficacious vasoconstrictor agents compared with Ang II. Endogenous aminopeptidase activity may counteract the effects of the angiotensin peptides. The contractile responses to all three peptides are mediated via AT(1)-receptors but not AT(2)-receptors.